"Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning. He has been piling into , and as of late, and we'll get into why. Druckenmiller first gained fame by managing George Soros's Quantum Fund, where he orchestrated the $10 billion currency bet that "broke the Bank of England" in 1992. Since founding Duquesne Capital Management in 1981, he's delivered annualized returns exceeding 30% before closing to outside investors in 2010."
"Druckenmiller's biggest holding is Natera. It is a clinical genetic testing company that specializes in non-invasive, cell-free DNA (cfDNA) testing technology. NTRA stock has been one of Druckenmiller's biggest winning moves as it has gained over 500% since bottoming out in October 2023. Druckenmiller built up his stake as the stock traded sideways throughout late 2022 to early 2023. As NTRA stock finally broke out and started rallying, Druckenmiller kept adding to his stake ."
"The stock has gained nearly 70% since that dip and is continuing to rally higher. Growth has been very strong . Revenue grew 34.66% year-over-year in Q3 2025 and beat analyst estimates. Natera is still loss-making, but analysts expect losses to narrow. EPS is expected to turn positive in 2028 with revenue continuing to grow by double digits through the next decade. NTRA stock constitutes 12.74% of Druckenmiller's portfolio. His holdings here are worth $517.4 million ."
Stanley Druckenmiller achieved fame by managing the Quantum Fund and orchestrating the $10 billion 1992 currency bet that broke the Bank of England. Duquesne Capital delivered annualized returns exceeding 30%. Natera is his largest holding; it specializes in non-invasive, cell-free DNA testing and gained over 500% since bottoming in October 2023. He accumulated the stake in late 2022 and early 2023, trimmed in Q1 and Q2 2025, and repurchased in Q3 2025. NTRA comprises 12.74% of his portfolio, valued at $517.4 million. Natera reported 34.66% revenue growth year-over-year in Q3 2025, remains loss-making, and expects EPS to turn positive by 2028. Insmed focuses on pulmonary conditions with ARIKAYCE as its flagship product.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]